Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Over 60% of Cancer Patients Aware of Generic Cancer Treatment Options: Sawai Survey
July 5, 2013
- Fujifilm to Begin PIII Study of Personalized Peptide Cancer Vaccine
July 5, 2013
- AY Pharmaceuticals Starts Operations, Yoshindo Bolsters Sales, Marketing System
July 5, 2013
- Hanshin DP Holdings, Medical System Network Establish New JV to Support Efficient Distribution
July 5, 2013
- Importance of Personal Relationships, Low Use of Generics Contribute to Persistence of SOV Model in Japan, but Change is Likely
July 5, 2013
- MTPC Begins Construction of New Head Office Building, Expects Completion in January 2015
July 4, 2013
- Generic Industry Needs to Produce 30 Billion More Tablets to Meet 60% Generic Share Goal: Sawai President
July 4, 2013
- Out-Licensed OAB Treatment Imidafenacin Launched in South Korea: Kyorin Holdings
July 4, 2013
- Low-Dose Lunabell Approved
July 4, 2013
- Manipulation of BMI Data in Kobayashi Pharmaceutical’s Anti-Obesity Drug Clinical Study Suspected
July 3, 2013
- Sandoz to Ratchet Up Promotions for General Practitioners, Dispensing Pharmacies
July 3, 2013
- Latuda Approved for Major Depressive Episodes Associated with Bipolar I Disorder in the US: DSP
July 3, 2013
- Japanese Society of Chemotherapy Joins Hands with Pharmas, Govt to Spur New Antibiotic Development
July 2, 2013
- DSP Adopts Tokyo-Osaka Two Head Office System
July 2, 2013
- Takeda Withdraws European MAA for Anemia Treatment Peginesatide Following Voluntary Recall in US
July 2, 2013
- Gout, Hyperuricemia Treatment Topiloric/Uriadec Tablets Approved: Fuji Yakuhin, Sanwa Kagaku
July 2, 2013
- Astellas’ US Affiliate Agensys to Codevelop ADC with Seattle Genetics
July 1, 2013
- Kyowa Kirin Files NDA for Sustained-Duration G-CSF KRN125, PEGylated Form of Gran
July 1, 2013
- Takeda President Executive Pay Reaches 300 Million Yen, Three Execs Receive Over 700 Million Yen
June 28, 2013
- Novartis Files Combination Drug for Parkinson’s Disease in Japan
June 28, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…